Yang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yang Chen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Yongsheng Li
Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, China
17 shared publications - Huakan Zhao
Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, China
16 shared publications - Yu Zhou
Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China
16 shared publications - Bing Sun
Nanjing Aoyin Biotechnology Co., Ltd., Nanjing, China
15 shared publications - Jiangang Zhang
Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China
15 shared publications - Jinwei Cui
Nanjing Aoyin Biotechnology Co., Ltd., Nanjing, China
15 shared publications
Latest Publications
- 10 July 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (33) , 3439-3455
MTAP deficiency enhances collective metastasis in non-small cell lung cancer via WNT3A methylation
Collective cell migration (CCM) is a pivotal driver of tumor progression and metastasis in non-small cell lung cancer (NSCLC), yet its upstream regulatory mechanisms remain poorly understood. Here, we investigated the functional role and molecular mechanism of MTAP deficiency in modulating CCM in NSCLC. Clinical sample analysis revealed that NSCLC patients with MTAP deficiency exhibited significantly shorter overall survival. Using a three‑dimensional culture system, we verified that MTAP deficiency had little effect on cell proliferation, but markedly promoted CCM by inducing cytoskeletal rearrangement of leader cells within tumor clusters. Mechanistically, MTAP deletion leads to intracellular MTA accumulation, which suppresses PRMT5 activity and reduces global protein symmetric dimethylarginine (sDMA) modification. Decreased sDMA further enhances USF2 phosphorylation and nuclear translocation, facilitates USF2 binding to the WNT3A promoter, and concurrently reduces DNA CpG methylation of the WNT3A promoter, thereby synergistically activating WNT3A transcription. Upregulated WNT3A strengthens intercellular crosstalk between leader and follower cells, elevates adhesion among follower cells, and drives cytoskeletal remodeling in leader cells, ultimately accelerating CCM progression. Pharmacologically, the WNT3A specific inhibitor C59 effectively blocked CCM formation and mitigated collective metastasis in MTAP‑deficient NSCLC. In summary, our results define a novel MTAP–PRMT5–sDMA–WNT3A regulatory axis that controls CCM and malignant progression of NSCLC. Targeting WNT3A represents a promising therapeutic strategy for the clinical treatment of MTAP‑deficient NSCLC.
- 10 July 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (33) , 3439-3455
MTAP deficiency enhances collective metastasis in non-small cell lung cancer via WNT3A methylation
Collective cell migration (CCM) is a pivotal driver of tumor progression and metastasis in non-small cell lung cancer (NSCLC), yet its upstream regulatory mechanisms remain poorly understood. Here, we investigated the functional role and molecular mechanism of MTAP deficiency in modulating CCM in NSCLC. Clinical sample analysis revealed that NSCLC patients with MTAP deficiency exhibited significantly shorter overall survival. Using a three‑dimensional culture system, we verified that MTAP deficiency had little effect on cell proliferation, but markedly promoted CCM by inducing cytoskeletal rearrangement of leader cells within tumor clusters. Mechanistically, MTAP deletion leads to intracellular MTA accumulation, which suppresses PRMT5 activity and reduces global protein symmetric dimethylarginine (sDMA) modification. Decreased sDMA further enhances USF2 phosphorylation and nuclear translocation, facilitates USF2 binding to the WNT3A promoter, and concurrently reduces DNA CpG methylation of the WNT3A promoter, thereby synergistically activating WNT3A transcription. Upregulated WNT3A strengthens intercellular crosstalk between leader and follower cells, elevates adhesion among follower cells, and drives cytoskeletal remodeling in leader cells, ultimately accelerating CCM progression. Pharmacologically, the WNT3A specific inhibitor C59 effectively blocked CCM formation and mitigated collective metastasis in MTAP‑deficient NSCLC. In summary, our results define a novel MTAP–PRMT5–sDMA–WNT3A regulatory axis that controls CCM and malignant progression of NSCLC. Targeting WNT3A represents a promising therapeutic strategy for the clinical treatment of MTAP‑deficient NSCLC.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Statistical information related to Fig.1F and 1G
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Statistical information related to Fig.1F and 1G
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Comparison of the TME of HR and LR using IMC data.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Comparison of the TME of HR and LR using IMC data.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
The workflow of integrative single-cell PTM omics
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
The workflow of integrative single-cell PTM omics
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Summary of clinicopathological information and characteristics of the enrolled 53 patients with HCC
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Summary of clinicopathological information and characteristics of the enrolled 53 patients with HCC
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Metal antibodies used for IMC.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Metal antibodies used for IMC.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
The expression levels of phosphorylated HSP27 (p-HSP27, S82), phosphorylated STAT1 (p-STAT1, S727), and phosphorylated TRIM28 (p-TRIM28, S473) in TAMs
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
The expression levels of phosphorylated HSP27 (p-HSP27, S82), phosphorylated STAT1 (p-STAT1, S727), and phosphorylated TRIM28 (p-TRIM28, S473) in TAMs
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Comparison of the spatial feature TME of HR and LR using IMC data.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Comparison of the spatial feature TME of HR and LR using IMC data.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Proportion of immune cells in CT versus AT.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Proportion of immune cells in CT versus AT.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Subtyping M2 macrophages based on profiles of p-HSP27, p-STAT1, and p-TRIM28.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment
Subtyping M2 macrophages based on profiles of p-HSP27, p-STAT1, and p-TRIM28.